Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

367
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
367
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

627
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

535
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
535
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

429
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
429
Factors Affecting Drug Biotransformation: Biological01:19

Factors Affecting Drug Biotransformation: Biological

909
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
909
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

230
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
230

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma CXCL13 and fibrosis biomarkers in COVID-19 compared with idiopathic pulmonary fibrosis.

Scientific reports·2026
Same author

High Nasopharyngeal SARS-CoV-2 Load and Delayed Clearance in Hospitalized Patients With Blood Autoantibodies Neutralizing Type I Interferons.

The Journal of infectious diseases·2026
Same author

Objective First, Method Second: Why the Estimand Definition Comes First in Pharmacometric Covariate Modeling.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Assessing Covariate Clinical Relevance in High-Dimensional PK Analysis: A Comparison of SCM+, FFEM, and FREM Approaches.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Advances and Further Comparison of Software Tools for Fisher Information Matrix-Based Design Evaluation in Pharmacometrics.

Pharmaceutical research·2026
Same author

Levels of circulating kidney injury markers and IL-10 identify non-critically ill patients with COVID-19 at risk of death.

JCI insight·2026

Related Experiment Video

Updated: Apr 26, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K

Scientific factors and current issues in biosimilar studies.

Shein-Chung Chow1, Laszlo Endrenyi, Peter A Lachenbruch

  • 1a Department of Biostatistics and Bioinformatics , School of Medicine, Duke University , Durham , North Carolina , USA.

Journal of Biopharmaceutical Statistics
|August 8, 2014
PubMed
Summary

Assessing biosimilarity requires careful consideration due to the complexity of biological drugs. This review examines scientific factors and current issues in evaluating biosimilarity and interchangeability for drug products.

Keywords:
BioequivalenceBiosimilarityBiosimilarity indexMoment-based approachProbability-based approachTotality of the evidence

More Related Videos

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

1.9K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.8K

Related Experiment Videos

Last Updated: Apr 26, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K
Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

1.9K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.8K

Area of Science:

  • Biopharmaceuticals
  • Drug Development
  • Regulatory Science

Background:

  • Biological drugs are complex, large molecules sensitive to environmental factors and potentially immunogenic, unlike small-molecule drugs.
  • Assessing biosimilarity demands greater scrutiny than bioequivalence studies for conventional drugs.

Purpose of the Study:

  • To discuss scientific factors and current issues in the assessment of biosimilarity and interchangeability of biological drug products.
  • To explore criteria, study designs, and analytical approaches for evaluating drug product similarity and comparability.

Main Methods:

  • Review of scientific literature and current regulatory considerations for biosimilarity assessment.
  • Discussion of endpoint selection, similarity criteria, study designs (e.g., crossover, parallel), and totality of evidence approaches.
  • Examination of critical quality attributes, reference standards, and sample size calculations.

Main Results:

  • Biosimilarity assessment requires a flexible approach, evaluating the degree of similarity and employing a totality of evidence strategy.
  • Current issues include defining criteria for biosimilarity, interchangeability, comparability, and selecting appropriate reference standards.
  • Appropriate study designs and statistical methods, including sample size calculations, are crucial for robust biosimilarity evaluations.

Conclusions:

  • A comprehensive, stepwise approach using totality of evidence is essential for determining biosimilarity and interchangeability.
  • Addressing scientific factors like endpoint selection and flexibility in evaluation is key to robust biosimilarity assessments.
  • Further refinement of criteria and methodologies will enhance the evaluation of complex biological drug products.